AI Overview · plain answer
Pluvicto is the Novartis brand name for the radioligand therapy Lu-177 PSMA-617. It does not cure prostate cancer, but in carefully selected men whose cancer is PSMA-positive on a PET scan, it controls the disease and extends survival.
Success rate: in the VISION trial, about 46% of men had a PSA50 response (PSA fell by at least half) and 71.5% had some PSA decline.
Life expectancy: median overall survival was 15.3 months with Pluvicto plus standard care, versus 11.3 months without (hazard ratio 0.62).
Cost: about US$27,000 per cycle in the United States; at our centre in India, Indian-source Lu-177 PSMA starts from ₹75,000 per cycle.
Important
This page explains averages from clinical trials. It is general information, not medical advice, and it cannot tell you how Pluvicto will work for one person. Treatment decisions need a nuclear medicine specialist who has reviewed the PSMA-PET scan and blood work.
What ‘success rate’ actually means
“Success” with Pluvicto is measured in a few different ways, and it helps to keep them apart. The clearest patient-level signal is the PSA response. In VISION — the phase 3 trial that led to approval — about 46% of men had a PSA50 response (PSA dropped by at least half), and 71.5% had some PSA decline, compared with 35.5% on standard care alone.[1][6]
For men with measurable tumours, the cancer shrank in roughly half: a complete response in 9% and a partial response in 40%.[6] The disease was also held in check for longer — median radiographic progression-free survival of 8.7 months versus 3.4 months on standard care.[1] Reassuringly, a real-world US programme of 117 patients found almost the same PSA50 rate (42%) as the trial.[4]
What none of these figures mean is a cure. A response is a meaningful, often months-long period of disease control and symptom relief — not the elimination of the cancer.
Pluvicto life expectancy and survival
The headline number families ask about is survival. In VISION, adding Pluvicto to standard care extended median overall survival to 15.3 months, versus 11.3 months for standard care alone — a hazard ratio of 0.62 (95% CI 0.52–0.74), meaning the risk of death over the study was reduced by about 38%.[1] The FDA summarised this as men living “about 15 months compared to 11 months.”[2]
The word median matters. It is the midpoint: half of the men lived longer than 15.3 months, some considerably so, and the trial enrolled men who had already had hormone therapy and chemotherapy — a heavily pre-treated group. A US real-world cohort saw an almost identical median of 15.1 months,[4] which is unusual and reassuring agreement between a trial and everyday practice.
| VISION outcome |
Pluvicto + standard care |
Standard care alone |
| Median overall survival |
15.3 months |
11.3 months |
| Median radiographic PFS |
8.7 months |
3.4 months |
| Any PSA decline |
71.5% |
35.5% |
| Tumour response (complete + partial) |
~49% (9% complete) |
~1.6% |
How to read these numbers
These are pooled averages from one large trial, not a forecast for any individual. A man’s own life expectancy on Pluvicto depends on how much cancer he has, how strongly it expresses PSMA, his kidney and marrow reserve, and his general fitness. Men treated earlier and in better health tend to do better than the trial average.
How much does Pluvicto cost?
Pluvicto is given as an intravenous infusion at a standard dose of 7.4 GBq (200 mCi) once every six weeks, for up to six cycles; in practice most men receive four to six cycles, so the cost is usually quoted per cycle.[2]
In the United States, published pharmacoeconomic analysis puts the drug at about US$27,000 per cycle (one vial), and with a mean of 4.54 cycles per patient in VISION, roughly US$122,489 for a full course, plus about US$1,200 for the PSMA-PET scan used to select patients.[3] Actual out-of-pocket cost varies widely with insurance; Novartis runs a copay programme under which eligible commercially insured patients may pay as little as US$0 per dose (up to a US$15,000 maximum).[7]
At our centre in India, the cost depends on which source of Lu-177 PSMA is used:
- Indian-source Lu-177 PSMA — ₹75,000 per cycle for Indian patients (about ₹4,50,000 for a six-cycle course).
- German-source (the Pluvicto-equivalent validated in VISION) — about ₹5,85,000 per cycle for Indian patients, and ₹6,50,000 (USD 7,222) per cycle for international patients, up to about ₹39,00,000 for a full course.
The two are chemically identical; the difference is the manufacturing supply chain. Indian-source material is produced under Indian regulatory oversight at substantially lower cost, while the German-source formulation is the one carried through the VISION trial and approved internationally as Pluvicto (FDA, March 2022; EMA, December 2022).[8] Our centre sources its German-source Lu-177 from ITM Isotope Technologies Munich SE — the same producer that supplies the isotope for Novartis’s Pluvicto, and one of the world’s largest Lu-177 production facilities; the Indian-source isotope is produced domestically at the Bhabha Atomic Research Centre (BARC).[9]
Why we don’t quote a single total
The number of cycles and the source used depend on your disease and eligibility, so we do not give a fixed total before reviewing the PSMA-PET and blood work. For a detailed India breakdown — including comparison with centres in Germany, Australia and the US — see our Lu-177 PSMA cost in India guide and the full Lu-177 PSMA therapy page.
Insurance & cashless cover in India
Lu-177 PSMA therapy in India is covered by most health insurers under cancer-treatment benefits, subject to your policy terms and pre-authorisation. Where the hospital is in the insurer’s cashless network — for the four public-sector insurers, the GIPSA (General Insurance Public Sector Association) Preferred Provider Network — standardised package rates apply. Confirm the applicable GIPSA / package rates with the hospital, and your specific coverage with your insurer, before committing to treatment.
What it costs in other countries
For international patients comparing options, the figures below are an approximate orientation only. Some sources quote a single cycle and others a full course, they usually exclude the PSMA-PET scan, travel and hospital stay, and they vary widely by centre and by the number of cycles a man needs (typically four to six).[11]
| Country / region |
Approximate published cost |
Notes |
| India (our centre) |
From ₹75,000 (~US$900) per cycle, Indian-source; German-source from ₹5,85,000 per cycle |
Among the lowest globally; indigenous BARC or ITM (German) isotope |
| Turkey |
~US$6,500–13,000 per course |
Lowest among major medical-tourism hubs |
| Israel |
~US$10,000–20,000 per cycle |
Established theranostics centres |
| Thailand & Malaysia |
Roughly double the India cost |
Per our own published comparison |
| EU (Germany, Austria…) |
~€22,700–44,000 per course |
High-cost; strong clinical experience |
| United Kingdom |
Up to ~US$44,000 per course (private) |
Outpatient theranostics; price on enquiry |
| United States |
~US$27,000 per cycle (drug); ~US$122,489 per course |
Insurance-dependent; copay programmes exist |
Waiting periods & supply
Access matters as much as price. Isotope supply constraints in 2022–2023 caused real delays in the US and parts of the EU — one US cancer-centre series recorded a median wait of roughly two to three months from the tumour-board decision to the first cycle.[10] India’s position is helped by indigenous Lu-177 production at the Bhabha Atomic Research Centre (BARC),[9] and Turkey, Israel and India generally offer shorter waits for self-paying international patients. Because each dose has a shelf life of only a few days from manufacture, every cycle has to be scheduled in close coordination with the isotope supplier.
“Families understandably ask whether it is worth it. The honest answer is that Pluvicto buys time and disease control for many men — months of meaningful survival in a phase 3 trial — but it is not a cure, and the right decision depends on the scan, the fitness, and the family’s goals.”
Dr. Ishita B. Sen · Director & Chief, Nuclear Medicine, FMRI
Who benefits most
Pluvicto is not equally effective for everyone. The men most likely to benefit share a few features:
- PSMA-positive disease — the cancer must clearly take up PSMA on a PSMA-PET scan. Around 80% of metastatic prostate cancers express PSMA, but the scan has to confirm it for the individual; this is the single most important gate.
- Good performance status — ECOG 0–1 (up and about, self-caring).
- Adequate organ reserve — sufficient bone-marrow and kidney function to tolerate the radiation dose.
- Treated at the right point — in the pre-chemotherapy PSMAfore trial, Lu-177 PSMA more than doubled radiographic progression-free survival (12.0 versus 5.6 months), suggesting earlier use can work well, though its earlier-line role is still being finalised by regulators.[5]
Pluvicto reviews: what to trust
Searching for “Pluvicto reviews” turns up patient anecdotes. They are genuinely useful for understanding what the experience feels like — the infusion itself, the dry mouth, the fatigue — but they are a poor guide to your result, because every man’s disease and prior treatment are different.
The signals worth weighting are the trial and real-world data above and, once treatment begins, your own PSA trend and follow-up PSMA-PET. The fact that a 117-patient real-world US cohort closely matched the trial (median survival 15.1 vs 15.3 months; PSA50 42% vs 46%) is more reassuring than any single testimonial.[4] For de-identified examples of measured responses at our own centre, see our Lu-177 PSMA & PRRT case studies.
Second Read · is Pluvicto right for this case?
If you or a family member has PSMA-positive prostate cancer and you are weighing Pluvicto (Lu-177 PSMA) — the likely benefit, the cost, and whether the timing is right — the nuclear medicine team at FMRI, Dr. Ishita B. Sen and Dr. Dharmender Malik, can review the PSMA-PET and blood work and give an honest, individual opinion.
Request a Second Read · WhatsApp +91 8800 988936
For patients & families
Frequently asked questions
Q01What is the success rate of Pluvicto?
In the VISION trial, about 46% of men had a PSA50 response — their PSA fell by at least half — and 71.5% had some PSA decline. Of men with measurable tumours, roughly half responded (a 9% complete and 40% partial response). Pluvicto controls disease in many men, but it is not a cure.
Q02What is the life expectancy with Pluvicto?
In VISION, median overall survival was 15.3 months with Pluvicto plus standard care versus 11.3 months with standard care alone (hazard ratio 0.62). Median is a midpoint — half of the men lived longer than this, and individual results vary widely with disease burden and fitness.
Q03How much does Pluvicto cost?
In the United States the drug alone is about US$27,000 per cycle, or roughly US$122,489 for a typical course, plus about US$1,200 for the PSMA-PET scan. At our centre in India, Indian-source Lu-177 PSMA starts from ₹75,000 per cycle (about ₹4,50,000 for six cycles); the German-source Pluvicto-equivalent costs more.
Q04Is Pluvicto a cure for prostate cancer?
No. Pluvicto controls disease and extends survival for many men with PSMA-positive metastatic castration-resistant prostate cancer, but it is not a cure. It is used when the cancer has spread and is no longer controlled by hormone therapy.
Q05Who responds best to Pluvicto?
Men whose cancer clearly takes up PSMA on a PSMA-PET scan, with good performance status (ECOG 0–1) and adequate kidney and bone-marrow function, tend to respond best. PSMA-PET positivity is the single most important requirement.
Q06How many Pluvicto treatments are needed?
Up to six cycles. Each is an intravenous infusion at a standard dose of 7.4 GBq (200 mCi), given once every six weeks. Treatment continues while it is helping and being tolerated; in practice most men receive four to six cycles, some stop earlier, and a few are eligible for re-treatment later.
Q07Does Pluvicto work in earlier-stage prostate cancer?
In the PSMAfore trial, given before chemotherapy, Lu-177 PSMA more than doubled radiographic progression-free survival (12.0 versus 5.6 months). Its earlier-line role is still being defined by regulators, and the overall-survival comparison there was confounded by trial crossover.
Q08Is Indian-source Lu-177 PSMA the same as Pluvicto?
The radioisotope and targeting molecule are chemically identical. The difference is the manufacturing supply chain and regulatory source. The German-source variant is the formulation validated in the VISION trial and marketed internationally as Pluvicto; Indian-source material is produced under Indian regulatory oversight at lower cost.
Evidence & references
[1] Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION).
N Engl J Med. 2021;385:1091–1103.
View source ↗[2] U.S. Food & Drug Administration. Drug Trials Snapshots: PLUVICTO.
View source ↗[3] CADTH. Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): Pharmacoeconomic Review — drug cost ~US$27,000 per cycle; ~US$122,489 per course; PSMA-PET ~US$1,200. 2023.
View source ↗[4] Real-world [177Lu]Lu-PSMA-617: U.S. Expanded Access Program vs VISION — median OS 15.1 vs 15.3 months; PSA50 42% vs 46%. SNMMI 2024.
View source ↗[5] Morris MJ, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus change of ARPI in taxane-naive mCRPC (PSMAfore).
Lancet. 2024;404(10459):1227–1239.
View source ↗[6] Novartis. PLUVICTO Prescribing Information — PSA and objective response (complete 9%, partial 40%; any PSA decline 71.5%).
View source ↗[7] Drugs.com. Pluvicto Prices, Coupons & Patient Assistance — copay programme ($0 per dose for eligible insured, max US$15,000).
View source ↗[8] Theranostic Physicians. Lu-177 PSMA Therapy — protocol, Indian- and German-source options and pricing.
View page ↗[9] 177Lu-PSMA-617 for metastatic prostate cancer in India — indigenous production at the Bhabha Atomic Research Centre (BARC) and imported isotope from ITM Isotope Technologies Munich SE (Germany), described as the world’s largest Lu-177 production facility. 2024.
View source ↗[10] Oncologists encounter challenges accessing PSMA-targeted therapy — 2022–23 supply shortages and treatment delays (Dana-Farber series).
Targeted Oncology. 2025.
View source ↗[11] Approximate international cost ranges compiled from published medical-tourism and health-economic estimates (Bookimed, Booking Health, Assuta) and our own published comparison, “Lowest cost of Lu-177 PSMA therapy in India.”
View source ↗Pluvicto® is a registered trademark of Novartis AG. This page is independent patient education by Theranostic Physicians and is not affiliated with, sponsored by, or endorsed by Novartis. The name is used for identification only; the therapy described is the Lu-177 PSMA-617 radioligand.
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · Director & Chief, Department of Nuclear Medicine, Fortis Memorial Research Institute
Dr. Sen leads the nuclear medicine and theranostics programme at FMRI, Gurugram, with a focus on PSMA and DOTATATE imaging and Lu-177 and Ac-225 radioligand therapy. She works alongside Dr. Dharmender Malik on patient selection, dosimetry and treatment planning in advanced prostate cancer.